Pfizer secures 1.5 billion dollars from Blackstone for obesity drug

Pfizer said Blackstone will provide up to 1.5 billion dollars through 2028 to fund development of berobenatide, its experimental monthly injectable obesity treatment, in return for milestone based payments and no ownership rights in the drug.

Why it matters: The financing shifts part of the development cost of Pfizer's main obesity hope off its own balance sheet while keeping full control of the programme, another sign of private credit moving into drug development funding.

Data as of Reuters report of November 11, 2026, read in full via the estate browser route in its Investing.com carrying. The size of the milestone payments was not disclosed. Developing item.

Pfizer said on Wednesday that Blackstone will provide up to 1.5 billion dollars through 2028 to help fund development of berobenatide, an experimental monthly injectable obesity treatment it picked up last year in its acquisition of Metsera, a deal worth up to 10 billion dollars. Pfizer said it will keep full control over the development programme and that the funding gives it more flexibility to invest across its wider pipeline.

Blackstone will be eligible for milestone based payments but will receive no rights or ownership in the medication. The payments depend on United States regulatory approval of monthly dosing of berobenatide as a monotherapy for chronic weight management and on the drug reaching certain commercial sales milestones, and their size was not disclosed.

Pfizer secures 1.5 billion dollars from Blackstone for obesity drug

Sources